Latest Breaking News On - Department of haematology - Page 1 : comparemela.com

Sanofi: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3

ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 Sarclisa, in combination

Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3

BrECADD Regimen Improves PFS vs eBEACOPP Regimen in Advanced Classical Hodgkin Lymphoma

Four-year progression-free survival outcomes revealed the BrECADD regimen was superior to the eBEACOPP regimen, and BrECADD had a promising benefit-risk profile.

BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Acoramidis treatment related increase in serum TTR is associated with lower cardiovascular mortality in ATTR CM

Treatment-Related Early Increase in Serum TTR is Associated With Lower Cardiovascular Mortality in ATTR-CM: Insights From ATTRibute-CM Amrut.

Phase 1 trial for EBC-129 progresses into dose expansion